Literature DB >> 9389920

Incidence of risk of thromboembolism during treatment high-grade gliomas: a prospective study.

A A Brandes1, E Scelzi, G Salmistraro, M Ermani, C Carollo, F Berti, P Zampieri, C Baiocchi, M V Fiorentino.   

Abstract

A prospective study of a series of 77 patients on adjuvant radiochemotherapy following surgery for high-grade gliomas was conducted to evaluate the risk of deep vein thrombosis and identify risk factors. We found a 20.8% risk of deep vein thrombosis at 12 months (standard error = 4.8%) and a 31.7% risk (standard error = 7.4%) at 24 months (Kaplan-Meier method). Twenty patients (26%) developed deep vein thrombosis with a maximum incidence within the first 7 months after surgery when chemotherapy was still being administered, often with corticosteroids. The risk factors identified were histology (glioblastoma versus anaplastic astrocytoma, P = 0.032, log rank test; 0.0485 L-ratio) and the presence of paresis (P = 0.010, log rank test; 0.0161 L-ratio). A borderline tendency was found for an association between the deep vein thrombosis site and the side of paresis (P = 0.103, Fisher's exact test). Four patients (5%) had massive pulmonary embolism, which was fatal in 3 (4%).

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9389920     DOI: 10.1016/s0959-8049(97)00167-6

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  56 in total

1.  Fatal pulmonary embolism despite an inferior vena cava filter in glioblastoma multiforme.

Authors:  Robert Cavaliere; David Schiff
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

2.  Venous thromboembolism in high grade glioma among surgical patients: results from a single center over a 10 year period.

Authors:  Timothy R Smith; Rishi R Lall; Randall B Graham; Jamal Mcclendon; Rohan R Lall; Allan D Nanney; Joseph G Adel; Anaadriana Zakarija; James P Chandler
Journal:  J Neurooncol       Date:  2014-07-26       Impact factor: 4.130

Review 3.  Practical management of bevacizumab-related toxicities in glioblastoma.

Authors:  Alba A Brandes; Marco Bartolotti; Alicia Tosoni; Rosalba Poggi; Enrico Franceschi
Journal:  Oncologist       Date:  2015-01-07

Review 4.  Medical management of patients with brain tumors.

Authors:  Patrick Y Wen; David Schiff; Santosh Kesari; Jan Drappatz; Debra C Gigas; Lisa Doherty
Journal:  J Neurooncol       Date:  2006-06-29       Impact factor: 4.130

5.  Radiation and concomitant weekly administration of paclitaxel in patients with glioblastoma multiforme. A phase II study.

Authors:  G Fountzilas; A Karavelis; A Capizzello; A Kalogera-Fountzila; G Karkavelas; N Zamboglou; P Selviaridis; G Foroglou; A Tourkantonis
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

Review 6.  The intertwined fates of inflammation and coagulation in glioma.

Authors:  Angela Cho; Kelly J McKelvey; Adrian Lee; Amanda L Hudson
Journal:  Mamm Genome       Date:  2018-07-30       Impact factor: 2.957

7.  Thromboembolic disease in patients with high-grade glioma.

Authors:  James R Perry
Journal:  Neuro Oncol       Date:  2012-09       Impact factor: 12.300

8.  Incidence of thromboembolic events after use of gelatin-thrombin-based hemostatic matrix during intracranial tumor surgery.

Authors:  Roberto Gazzeri; Marcelo Galarza; Carlo Conti; Costanzo De Bonis
Journal:  Neurosurg Rev       Date:  2017-04-24       Impact factor: 3.042

9.  Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma.

Authors:  Marc C Chamberlain; Sandra Johnston
Journal:  J Neurooncol       Date:  2008-10-25       Impact factor: 4.130

10.  Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme.

Authors:  Fabian Baumann; Miroslava Bjeljac; Spyros S Kollias; Brigitta G Baumert; Sebastian Brandner; Valentin Rousson; Yasuhiro Yonekawa; René L Bernays
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.